Several manuscripts have found that the combination of Vorinostat with aurora kinase inhibitors (AURK-Is) or TKIs kills primary CML cells, Baf3 cells expressing different BCR-ABL1 mutants and also shows antileukemic properties in CML mouse models. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.